Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 4
- Registration Number
- NCT00985530
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT00850304
- Locations
- 🇮🇷
Hematology-Oncology and SCT Research Center, Tehran, Iran, Islamic Republic of
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
- Conditions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT00720564
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT00671697
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT00670150
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00661544
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2016-02-19
- Target Recruit Count
- 9
- Registration Number
- NCT00582400
- Locations
- 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT00572065
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 9
- Registration Number
- NCT00571116
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.